Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 5/20 | 0.37 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | PRKCG | P05129 | 1/20 | 0.36 |
| ▸ | PRKCB | P05771 | 1/20 | 0.36 |
| ▸ | PRKCH | P24723 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15259620 | 1.00 | ALOX5 (0.55) | ALOX5ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL15259592 | 1.00 | ALOX5 (0.55) | ALOX5ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL15259595 | 1.00 | ALOX5 (0.55) | ALOX5ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL15259575 | 1.00 | ALOX5 (0.55) | ALOX5ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL15259577 | 1.00 | ALOX5 (0.55) | ALOX5ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL16656319 | 1.00 | ALOX5 (0.55) | ALOX5ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL15259624 | 1.00 | ALOX5 (0.55) | ALOX5ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL15259591 | 1.00 | ALOX5 (0.55) | ALOX5ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL15259625 | 1.00 | ALOX5 (0.55) | ALOX5ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL15259617 | 1.00 | ALOX5 (0.55) | ALOX5ALDH1A1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120027687-A1 | FATTY ACID PROTEIN KINASE C ACTIVATORS AND ANTICOAGULANT FOR THE TREATMENT OF STROKE | WEST VIRGINIA UNIVERSITY | 2012-02-02 | — | — | US | claimed |
| WO-2012006510-A1 | FATTY ACID PROTEIN KINASE C ACTIVATORS AND ANTICOAGULANT FOR THE TREATMENT OF STROKE | ALKON DANIEL L (US) | 2012-01-12 | — | — | WO | claimed |
| US-11826345-B2 | Dosing regimens of PKC activators | Synaptogenix, Inc. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11826345-B2 | Dosing regimens of PKC activators | Synaptogenix, Inc. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20210023048-A1 | DOSING REGIMENS OF PKC ACTIVATORS | COGNITIVE RESEARCH ENTERPRISES, INC. (US) | 2021-01-28 | — | — | US | disclosed |
| US-9119825-B2 | PKC-activating compounds for the treatment of neurodegenerative diseases | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2015-09-01 | — | — | US | disclosed |
| US-20140315990-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | COGNITIVE RESEARCH ENTERPRISES, INC. | 2014-10-23 | — | — | US | disclosed |
| US-20140315990-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | COGNITIVE RESEARCH ENTERPRISES, INC. | 2014-10-23 | — | — | US | disclosed |
| US-20140235496-A1 | STIMULUS-ELICITED GENOMIC PROFILE MARKERS OF A NEURODEGENERATIVE CONDITION | BLANCHETTE ROCKEFELLER NEUROSCIENCES DRIVE (US) | 2014-08-21 | — | — | US | disclosed |
| WO-2012006510-A1 | FATTY ACID PROTEIN KINASE C ACTIVATORS AND ANTICOAGULANT FOR THE TREATMENT OF STROKE | ALKON DANIEL L (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210023048-A1 | DOSING REGIMENS OF PKC ACTIVATORS | PRKCA, PRKCH, PRKCQ | ALOX5 2400/4885ALDH1A1 4374/4885LMNA 2436/4885 |
| US-20120027687-A1 | FATTY ACID PROTEIN KINASE C ACTIVATORS AND ANTICOAGULANT FOR THE TREATMENT OF STROKE | PRKCA, FABP7, PRKCZ | ALOX5 174/4885ALDH1A1 3610/4885LMNA 450/4885 |
| US-20140315990-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | PRKCH, PRKCB, PRKCA | ALOX5 3192/4885ALDH1A1 4622/4885LMNA 1261/4885 |
| US-11826345-B2 | Dosing regimens of PKC activators | PRKCA, PRKCH, PRKCQ | ALOX5 2400/4885ALDH1A1 4374/4885LMNA 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.